Ceazar@Ceazar_Black
$ALLR
> be Allarity in the eyes of the market
> still priced like the old mess
> but the company you are looking at now is structurally different
> and the CEO is running it like a compressed-timeline value creation exercise
> start with the basics
> ~$16M cash
> zero debt
> one class of common shares
> no warrant overhang except a tiny amount at very high strikes
> no toxic preferred stack
> no variable price death spiral nonsense
> this matters because in microcap biotech the cap table is usually the product
> here the product is the product
> enter Thomas Jensen
> walks into a real cleanup job
> and instead of telling fairy tales about 2030 he does the boring lethal stuff first
> cleans shop
> terminates anything that does not drive near-term shareholder value
> cuts waste
> cuts programs
> stops the bleeding
> burn quickly goes from ~1.4M per month to ~0.5M per month
> capex discipline
> lean ops
> no empire building
> one focus
> then he upgrades execution talent
> brings in Jeremy Graff PhD(Eli Lilly Oncology 16+ yrs/serial biotech entrepreneur)
> serious oncology experience
> not a resume ornament
> a signal that this is being run for outcomes
> now zoom out
> the company still raises small amounts sometimes
> but not with penny warrants
> not with toxic structures
> not with “financing as a lifestyle”
> it is controlled runway management
> and the key point
> the lead asset is funded through the next real inflection
> stenoparib into the data readout window
> people forget what market we are in
> PARP inhibitors are still not just a major category, but a growing one too
> expected to be $11-13B by 2030
> big money already validated the class
> the question is not “does PARP work”
> the question is “is this one differentiated enough to matter”
> stenoparib checks multiple differentiation boxes
> remarkably well tolerated compared to other PARPis and definitely compared to chemo
> oral pill
> quality of life matters in late stage disease
> fatigue shows up but the typical marrow toxicity profile looks meaningfully cleaner than peers
> and then the big one
> crosses the blood brain barrier
> most PARPis do not meaningfully do that
> brain mets and CNS involvement are where drugs go to die
> a brain-penetrant PARP is not a normal feature
> another big one
> activity is not limited to BRCA positive
> most people do not have BRCA mutations
> broadening beyond BRCA is where the real population is
> and it also changes the valuation math if the signal holds
> now look at the patient context
> these are not first-line patients
> multi-line(some even w 5+ lines of treatment)
> chemo (Platinum refractory resistant)
> prior PARPis like olaparib and niraparib
> prior Elahere in some cases
> “standard options exhausted” population
> and stenoparib still produces durable benefit
> this is the part the market keeps hand-waving away
> but durable benefit in refractory ovarian is the entire game
> so why is Jensen zeroing in on late-stage ovarian specifically
> because this is where “short term” in biotech actually exists
> short term in biotech means months to a year
> not 5 years
> ovarian late stage has bad options
> the bar for meaningful differentiation is lower than people want to admit
> and the FDA has precedent for approvals off strong phase 2 data in high unmet need settings
> notice the language and design choices
> this is not framed like a casual phase 2b
> phase 2b implies “cool story, see you in phase 3”
> this is being positioned like a registrational intent trial
> pivotal-minded
> dose work plus efficacy signal
> built to support a regulatory conversation
> and yes the current FDA/Makary posture matters
> less interest in dragging timelines when the signal is real
> more interest in efficiency when endpoints and populations make sense
> that aligns with Jensen’s playbook
> FDA notices
> adds the Fast Track layer
> fast track based on extreme durability signals in a population that often ends in hospice quickly(3-4 months left)
> when you can point to durable responses in a setting where survival is measured in months
> the FDA listens
> compare what the market rewards
> corcept relacorilant shows around a ~4 month benefit versus standard chemo
> stock adds 5 billion in market cap on that kind of incremental improvement
> the lesson is clear
> the market pays for even modest clinical deltas
> meanwhile other ovarian options
> immunotherapy combos and other regimens
> IV infusion
> meaningful side effects
> quality of life tradeoffs
> a well tolerated oral agent is not a small thing in this population, esp in monotherapy w/o chemo
> now address the “some patients didn’t do well” argument
> yes variability exists
> that is exactly why dose selection matters
> when you examine the dataset, BID dosing stands out
> the long duration responders are disproportionately in the BID cohort
> cohort 2 in the company’s framing
> and the dramatic early response example shows what the top end can look like
> practical dosing thesis
> 200mg morning + 400mg evening appears directionally correct from the responder cluster
> open question is whether 400mg + 400mg is needed or tolerable
> FDA Project Optimus forces dose exploration and justification
> start lower
> escalate rationally
> optimize benefit-risk
> this is not a bug
> this is how you design a near-term registrational path in 2026
> then there is the IP and durability of value
> patent expiry baseline around 2032
> but DRP-linked biomarker strategy can extend commercial defensibility for way longer
> because the value is not only the molecule
> it is molecule + selection engine
> which brings us to DRP
> the market treats DRP like a footnote
> it is not a footnote
> it is a separate asset with its own optionality
> and it is exactly the kind of thing that can create non-linear value if validated in a pivotal setting
> now the VA moment
> Veterans Administration is building a trial in SCLC
> originally niraparib in the design
> a billion-dollar PARPi
> and they switch to stenoparib!
> that is not retail speculation
> that is an external institution looking at tolerability, rationale, and fit in a chemo combo setting
> and deciding stenoparib is the better tool
> and then the real gift
> fully funded 166 patient study
> company provides drug product
> VA funds the rest
> 30-40M equivalent value of clinical execution you did not have to pay for
> another real shot on goal with asymmetric economics
> now address the 6M raise question head-on
> if you do simple math
> burn ~0.5M per month
> 12 months is ~6M
> ovarian trial cost roughly ~10M if you assume ~250k per patient for ~40 patients
> so why raise at all
> because public companies live and die by “going concern” language
> they need to show runway
> ideally 12 months plus
> and management prefers to avoid being forced into financing from weakness
> so the raise reads less like “we are running out of money”
> and more like “we are extending runway through 2027 so we control the timeline”
> and if the structure is no warrants and VWAP-tied
> the optimal execution is obvious
> do it into strength
> do it on a catalyst day
> do it when volume is massive
> let the VWAP be pulled upward by real demand
> raise the small amount without poisoning the cap table(say it goes to $5 raise ~1.25m shares at $4.75, almost nothing), no way he's doing it down here..
> this is Jensen’s entire pattern
> short term value creation
> timeline compression
> capital structure discipline
> don’t trade upside for survival financing
> and the punchline
> we have a clean cap table microcap biotech
> with a funded lead program into a real readout window
> in a validated drug class
> with tolerability differentiation
> Oral, no intravenous
> Monotherapy in ovarian, no chemo necessay
> BBB penetration differentiation
> activity beyond BRCA positive
> late-stage ovarian as the fastest regulatory path
> Fast Track as validation
> VA-funded SCLC as free upside
> DRP as a separate long-dated optionality layer
> market still pricing the ghost of the old company
> Jensen is running the rebuilt company like time is the asset
> and he is locked in on the only thing that matters
> months-to-a-year value inflection
> not a 5-year science project
> so yes, im buying this at below cash
